Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

Cemiplimab shows significant survival benefits over chemotherapy for advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression, enhancing treatment outcomes.

Patients with early-stage non–small cell lung cancer had improved outcomes after surgical treatment if they adhered to quality metrics associated with survival.